TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Depression, anxiety and stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in PTSD symptoms over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GMT and GMI of specific IgG total antibodies against SARS-CoV-2 variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GMT and GMI of neutralizing antibodies titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinically progressive pregnancy rate
Endpoint domain: Mortality/survival
Primary endpoint: Absolute change of the total score of the Brief Observation of Social Communication Change (BOSCC)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Percentage of participants that achieve biomarker-guided treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gene expression of NLRP3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cortisol (ug/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: C-reactive protein (mg/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate of intracervical balloon placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cross-sectional area of the long head of bicep tendon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of thoracic adverse events of special interest (TAEsSI) through 12 months
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of thoracic adverse events of special interest (TAEsSI) through 36 months
Endpoint domain: Adverse events/effects
Primary endpoint: plasma levels of Aβ peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: plasma levels of tau
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: plasma levels of glial fibrillary acidic protein (GFAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Anhedonia post-intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Anhedonia post-washout
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in RewP post-intervention measured via EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in RewP post-washout measured via EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation rates to the screening program
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to first occurrence of all-cause death, liver transplant, or hepatic decompensation
Endpoint domain: Mortality/survival
Primary endpoint: ventilation (Liters per minute)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistent Mixed Chimerism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % Time in Target Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Comfort Assessment In Dying scale (EOLD-CAD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Isometric muscle strength of rotator cuff muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: New T1 Gadolinium (Gd)-enhancing Lesions on Brain MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of New and/or Enlarging T2 Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Concordance index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight loss of 5% to 10% of body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in waist circumference (WC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal delivery <24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crying and fussing time data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rectal preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Disappearance rate of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of Pterostilbene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Time Curve From Time 0 to the Time t (AUC0-t) of TAK-279
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From Time 0 To Infinity (AUC0-inf) of TAK-279
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of TAK-279
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volumetric Periapical Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Etrumadenant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From 0 to Last Observed Non-zero Concentration [AUC(0-t)] of Etrumadenant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Time Curve From Time '0' Extrapolated to Infinity [AUC(0-inf)] of Etrumadenant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of death or intubation
Endpoint domain: Mortality/survival
Primary endpoint: Modified Rankin Scale (mRS) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Young modulus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local shear wave speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum diameter of gallbladder polyps at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum diameter of gallbladder polyps at week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to the COPD exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Detection of Cellular-Mediated Immune Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Measurement of canine retraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of molar anchorage loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of canine root resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Head-Capacity Curve (HCC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from MALE+POD
Endpoint domain: Mortality/survival
Primary endpoint: Composite of Limb Salvage and Primary Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: predictive value of FeNO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: predictive value of blood eosinophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: predictive value of TIgE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Stress Reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stress Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ATP level in sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of PORC related to age
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of PORC related to OSAS severity
Endpoint domain: Adverse events/effects
Primary endpoint: Development of cognitive knowledge about patient safety
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Development of patient safety competency
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Determining students' views on patient safety
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: pathological diagnosis accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in preoperative anxiety level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in alkaline phosphatase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot Joint Opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart Rate during Passive 10-min. standing test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood Pressure during Passive 10-min. standing test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Self-estimated level of Quality of Life: EQ-5D-5L: Index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of peri-operative bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with drug-related TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Youth Emotional and Behavioral Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Youth Academic Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Parenting Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Occurrence of clinically relevant events (number)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in total medical expenditures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes in Biometric Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in self-reported health behaviors and levels of motivation and confidence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Learning, Social and Emotional Adaptation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Emotional Development
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: clusters of type 2 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak plasma concentration of JYP0061
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change level of IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Average rate of stent migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Hepatitis B viral load results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to guidelines in difficult airway management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in molar position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average eye inflammatory symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Discontinuing Study Treatment due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Concentration-Time Curve from 0 to 24 hours (AUC0-24) of MK-1167 after Multiple Doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients avoiding opioid use
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of children with a severe complication (death or secondary hospitalisation) by Day 7
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of children admitted to hospital within 24 hours of the Day 0 primary care consultation and as a result of a referral
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Bacteriological cure, absence of TB treatment failure or relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportional of adverse events (AE) of grade 3 severity or higher
Endpoint domain: Adverse events/effects
Primary endpoint: changes in cognitive levels
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Correction of Maxillary Anterior Teeth Crowding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Inflammatory and Type I IFN Gene Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Methamphetamine Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Immediate AEs for 30 minutes post-vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Wound healing environment composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical evaluation of filling materials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with early anastomotic leakage
Endpoint domain: Adverse events/effects
Primary endpoint: Serological response for HBeAg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Degree of pain perception during IUD insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GMT of neutralizing antibodies against live SARS-CoV-2 virus on day 14 after the booster dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Successful puncture site haemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Freedom from major complications of the access site limb
Endpoint domain: Adverse events/effects
Primary endpoint: Disability and functional independence using Barthel ADL score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Short-term Change in Caregiver Distress with Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Long-term Change in Caregiver Distress with Behaviors (3-Months)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Short-Term Change in Caregiver Confidence Managing Behavioral and Psychological Symptoms of Dementia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Long-Term Change in Caregiver Confidence Managing Behavioral and Psychological Symptoms of Dementia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Short-Term Change in Person Living with Dementia- Frequency and Severity of Behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat Mass Percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat-Free Mass Percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of immunoglobulin g
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Obsessive beliefs scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Thought control scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: antibiotic-free days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of participants with TEAEs leading to withdrawal of investigational medicinal product (IMP)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Immunoglobulin E (IgE)-Mediated, Immediate-Type Food Allergy
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Atopic Dermatitis (AD)
Endpoint domain: Adverse events/effects
Primary endpoint: Absence of adverse effect
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Clinically Significant Changes in Clinical Laboratory Values
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the Concentration-Time Curve from Time 0 to 48 hours (AUC0-48hrs) of Levothyroxine (total T4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Levothyroxine (total T4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time to Maximum Plasma Concentration (Tmax) of Levothyroxine (total T4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area under the Concentration-Time Curve from Time 0 to 48 hours (AUC0-48hrs) of Triiodothyronine (total T3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Infusion limiting toxicities (ILTs)
Endpoint domain: Adverse events/effects
Primary endpoint: BBPS score of 6 or greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from kidney function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Correlation between LUSS and PaO2/FiO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of IVUS assessment success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of IVUS assessment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of intestinal Faecalibacterium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: thyroid nodule volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dual-Task Impact on Daily-living Activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maxillary arch dimension change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from intubation to tracheotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Net-Leucine Retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Bullous pemphigoid disease area index (BPDAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Highest Dose of Peanut Tolerated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in skin quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Distance between right and left inner surface of the lateral mass of the atlas and the outer surface of the odontoid process of the axis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative glucocorticoid doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in dynamic muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in isometric muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in muscle activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bertolotti's Syndrome-specific kinematic biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: real-time VAS data
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: aortic-related reintervention
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Mental Wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SBP AUC 0-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in sympathetic and parasympathetic nervous systems
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Lung cancer mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Self-perceived general health status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-perceived catheter-related experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Found the Study Overall Favorable
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Participants Who Would Recommend the Study
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ratings of Text Message Content Areas
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Global rating of perceived recovery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of patients obtaining remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early Visual Functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in CD4+T cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Heart rate and rhythm response to exercise and positional changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood pressure response to exercise and positional changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Activity metabolic equivalent of task (MET) tolerated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes